Sierra Health Care Center | |
1400 North Silver Street, T Or C, New Mexico 87901 | |
(575) 894-7855 | |
Name | Sierra Health Care Center |
---|---|
Location | 1400 North Silver Street, T Or C, New Mexico |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 90 |
Occupancy Rate | 63.89% |
Medicare ID (CCN) | 325062 |
Legal Business Name | Sierra Health Care Inc. |
Ownership Type | Non Profit - Corporation |
NPI Number | 1225742315 |
Organization Name | PALOMA SPRINGS HEALTHCARE LLC |
Address | 1400 Silver St, Truth Or Consequences, NM 87901 |
Phone Number | 575-894-7855 |
News Archive
Many women with a faulty breast cancer gene could be at greater risk of the disease due to extra 'risk amplifying' genes, according to research published in the American Journal of Human Genetics today.
Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's applications for six new presentations of therapeutic heparin in single- and multiple-dose vials.
The American Association for Homecare endorses the new "Prevent Health Care Fraud Act of 2009," S. 2128, which is designed to substantially improve tools and resources available to prevent fraud in Medicare. The bill was introduced by Sen. George LeMieux (R-Fla.).
Cepheid today announced that it has received clearance from the U.S. Food & Drug Administration to market Xpert CT/NG. Running on Cepheid's GeneXpert Systems, Xpert CT/NG is a qualitative in vitro molecular diagnostic test for the detection and differentiation of Chlamydia trachomatis and Neisseria gonorrhoeae. For the first time, same-day patient consultation and treatment is possible for the two most common sexually transmitted bacterial infections in the United States.
A specialist £20 million research centre, funded by the Wolfson Foundation and dedicated to carrying out first-in-human studies, opens in London today (15th November). Researchers at the Leonard Wolfson Experimental Neurology Centre (LWENC) will investigate exciting new therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's.
› Verified 6 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Many women with a faulty breast cancer gene could be at greater risk of the disease due to extra 'risk amplifying' genes, according to research published in the American Journal of Human Genetics today.
Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's applications for six new presentations of therapeutic heparin in single- and multiple-dose vials.
The American Association for Homecare endorses the new "Prevent Health Care Fraud Act of 2009," S. 2128, which is designed to substantially improve tools and resources available to prevent fraud in Medicare. The bill was introduced by Sen. George LeMieux (R-Fla.).
Cepheid today announced that it has received clearance from the U.S. Food & Drug Administration to market Xpert CT/NG. Running on Cepheid's GeneXpert Systems, Xpert CT/NG is a qualitative in vitro molecular diagnostic test for the detection and differentiation of Chlamydia trachomatis and Neisseria gonorrhoeae. For the first time, same-day patient consultation and treatment is possible for the two most common sexually transmitted bacterial infections in the United States.
A specialist £20 million research centre, funded by the Wolfson Foundation and dedicated to carrying out first-in-human studies, opens in London today (15th November). Researchers at the Leonard Wolfson Experimental Neurology Centre (LWENC) will investigate exciting new therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's.
› Verified 6 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 1 |
Total Amount of Fines in Dollars | $19173 |
Number of Payment Denials | 0 |
Total Number of Penalties | 1 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 17.83 | 14.46 |
Percentage of long-stay residents who lose too much weight | 8.33 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 40.21 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.41 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 2.21 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 8.74 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 6.44 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.86 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 21.68 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 83.96 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 9.26 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 23.12 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 14.88 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 6.1 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 95.11 | 95.98 |
Percentage of short-stay residents who made improvements in function | 77.54 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 81.25 | 82.93 |
News Archive
Many women with a faulty breast cancer gene could be at greater risk of the disease due to extra 'risk amplifying' genes, according to research published in the American Journal of Human Genetics today.
Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's applications for six new presentations of therapeutic heparin in single- and multiple-dose vials.
The American Association for Homecare endorses the new "Prevent Health Care Fraud Act of 2009," S. 2128, which is designed to substantially improve tools and resources available to prevent fraud in Medicare. The bill was introduced by Sen. George LeMieux (R-Fla.).
Cepheid today announced that it has received clearance from the U.S. Food & Drug Administration to market Xpert CT/NG. Running on Cepheid's GeneXpert Systems, Xpert CT/NG is a qualitative in vitro molecular diagnostic test for the detection and differentiation of Chlamydia trachomatis and Neisseria gonorrhoeae. For the first time, same-day patient consultation and treatment is possible for the two most common sexually transmitted bacterial infections in the United States.
A specialist £20 million research centre, funded by the Wolfson Foundation and dedicated to carrying out first-in-human studies, opens in London today (15th November). Researchers at the Leonard Wolfson Experimental Neurology Centre (LWENC) will investigate exciting new therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's.
› Verified 6 days ago
Sierra Health Care Center Location: 1400 North Silver Street, T Or C, New Mexico 87901 Phone: (575) 894-7855 |